The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

vTv Therapeutics, a biopharmaceutical company based in High Point, has received clearance from the U.S. Food and Drug ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52Opthea considering impact of negative trial ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 ...

Q4 2024 Management View Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment of relapsed and refractory ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...

Signal12 Pharmaceuticals has aligned with the FDA on its phase 3 clinical trial strategy for Pro-ocular, a novel drop-free ...

Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal ...